These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 24669014)

  • 1. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
    Yang CZ; Ma J; Zhu DW; Liu Y; Montgomery B; Wang LZ; Li J; Zhang ZY; Zhang CP; Zhong LP
    Ann Oncol; 2014 Jun; 25(6):1215-22. PubMed ID: 24669014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade.
    Zhu DW; Liu Y; Yang X; Yang CZ; Ma J; Yang X; Qiao JK; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
    BMC Cancer; 2013 Jun; 13():301. PubMed ID: 23786757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease.
    Zhong LP; Zhu DW; William WN; Liu Y; Ma J; Yang CZ; Yang X; Wang LZ; Li J; Myers JN; Lee JJ; Zhang CP; Zhang ZY
    Mol Cancer Ther; 2013 Jun; 12(6):1112-21. PubMed ID: 23515614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stathmin guides personalized therapy in oral squamous cell carcinoma.
    Ju WT; Ma HL; Zhao TC; Liang SY; Zhu DW; Wang LZ; Li J; Zhang ZY; Zhou G; Zhong LP
    Cancer Sci; 2020 Apr; 111(4):1303-1313. PubMed ID: 31994271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal BMI predicts the survival benefits of inductive docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced oral squamous cell carcinoma.
    Zhao TC; Liang SY; Ju WT; Liu Y; Tan YR; Zhu DW; Zhang CP; Zhang ZY; Zhong LP
    Clin Nutr; 2020 Sep; 39(9):2751-2758. PubMed ID: 31839432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
    Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Wang LZ; Fan XD; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Wang BS; Kies MS; Lee JJ; Myers JN; Zhang ZY
    J Clin Oncol; 2013 Feb; 31(6):744-51. PubMed ID: 23129742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of sensitivity to cisplatin, docetaxel, and 5-fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression.
    Zhao TC; Zhou ZH; Ju WT; Liang SY; Tang X; Zhu DW; Zhang ZY; Zhong LP
    Cancer Sci; 2022 Feb; 113(2):478-488. PubMed ID: 34826159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
    Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Hong CS; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Yin QM; Wang LZ; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Zhuang Z; Lee JJ; Myers JN; Zhang ZY
    Oncotarget; 2015 Jul; 6(21):18707-14. PubMed ID: 26124084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated growth differentiating factor 15 expression predicts long-term benefit of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy in patients with oral cancer.
    Tang X; Hu YJ; Ju WT; Fu Y; Sun WW; Liu Y; Tan YR; Wang LZ; Li J; Tu YY; Zhang CP; Zhang ZY; Zhong LP
    Oncol Lett; 2018 May; 15(5):8118-8124. PubMed ID: 29731919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma.
    Yang CZ; Ma J; Luo QQ; Neskey DM; Zhu DW; Liu Y; Myers JN; Zhang CP; Zhang ZY; Zhong LP
    J Oral Pathol Med; 2014 Jan; 43(1):28-34. PubMed ID: 23710769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
    Sun W; Zhao T; Aladelusi TO; Ju W; Zhang Z; Zhong L; Zhu D
    J Oral Pathol Med; 2021 Sep; 50(8):795-802. PubMed ID: 34157171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma.
    Luo SD; Chen YJ; Liu CT; Rau KM; Chen YC; Tsai HT; Chen CH; Chiu TJ
    Biomed Res Int; 2015; 2015():508587. PubMed ID: 26491674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
    Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
    N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phospholipase C gamma 1 is a potential prognostic biomarker for patients with locally advanced and resectable oral squamous cell carcinoma.
    Zhu D; Tan Y; Yang X; Qiao J; Yu C; Wang L; Li J; Zhang Z; Zhong L
    Int J Oral Maxillofac Surg; 2014 Dec; 43(12):1418-26. PubMed ID: 25085076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth differentiation factor 15 as a radiation-induced marker in oral carcinoma increasing radiation resistance.
    Schiegnitz E; Kämmerer PW; Rode K; Schorn T; Brieger J; Al-Nawas B
    J Oral Pathol Med; 2016 Jan; 45(1):63-9. PubMed ID: 25880686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
    Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
    N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
    Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients.
    Wen J; Xu H; Liu R; Chen Q; Dai Y; Xu Y
    Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):24-31. PubMed ID: 32538743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin D1 overexpression enhances chemosensitivity to TPF chemotherapeutic agents via the caspase-3 pathway in oral cancer.
    Hu YJ; Sun WW; Zhao TC; Liu Y; Zhu DW; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
    Oncol Lett; 2020 Nov; 20(5):154. PubMed ID: 32934722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
    Cullen KJ; Schumaker L; Nikitakis N; Goloubeva O; Tan M; Sarlis NJ; Haddad RI; Posner MR
    J Clin Oncol; 2009 Dec; 27(36):6222-8. PubMed ID: 19917838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.